Cost-utility analysis of adjuvant therapies for breast cancer in Iran

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 2, 2012, Pages 110-114

  Bastani, Peivand ^a   Kiadaliri, Aliasghar Ahmad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Breast Cancer; Cost utility; Iran; Quality adjusted life years

Indexed keywords

5-FLUOROURACIL; ADJUVANT THERAPY; BREAST CANCER; COST DATA; COST-UTILITY; COST-UTILITY ANALYSIS; DOCETAXEL; DOXORUBICIN; ECONOMIC EVALUATIONS; HEALTH-RELATED QUALITY OF LIVES; IRAN; NODE-POSITIVE; QUALITY-ADJUSTED LIFE YEARS; THIRD PARTIES; TIME HORIZONS;

COSTS; DETERIORATION; DISEASES; ECONOMIC ANALYSIS; HEALTH INSURANCE; HOSPITALS; PATIENT TREATMENT;

COST BENEFIT ANALYSIS;

ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COST BENEFIT ANALYSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; INFECTION; IRAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRAN; MIDDLE AGED; PSYCHOMETRICS; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84860780338     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462312000049     Document Type: Article

References (23)

1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
2. Au HJ, Golmohammadi K, Younis T, et al. Cost effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for nodepositive breast cancer: Modeling the downstream effects. Breast Cancer Res Treat. 2009;114:579-587.
3. Bastani P, Ahmad Kiadaliri A. Health related quality of life after chemotherapy cycle in breast cancer in Iran. Med Oncol. 2011:28(Suppl 1):S70-S74.
4. Brooks R. EuroQol: The current state of play. Health Policy. 1996;37:53-72. (Pubitemid 26191458)
5. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687-1717.
6. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-781.
7. Harirchi I, Karbakhsh M, Kashefi A, et al. Breast cancer in Iran: Results of a multi-center study. Asian Pac J Cancer Prev. 2004;5:24-27.
8. Harirchi I, Kolahdoozan S, Karbakhsh M, et al Twenty years of breast cancer in Iran: Downstaging without a formal screening program. Ann Oncol. 2001;22:93-97.
9. Hatam N, Ahmadloo N, Ahmad Kiadaliri A, et al. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet. 2011;284:215-220.
10. Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D. Mapping the cancer-specificEORTCQLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D Instruments. Value Health. 2009;12:1151-1157.
11. Larsson J, Sandelin K, Forsberg C. Health related quality of life and healthcare experiences in breast cancer patients in a study of Swedish women. Cancer Nurs. 2010;33:164-170.
12. Lee SG, Jee YG, Chung HC, et al. Cost effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: Docetaxel, doxorubicin, and cyclophosphamide(TAC) versus fluorouracil, doxurbicin and cyclophosphamide (FAC). Breast Cancer Res Treat. 2009;114:589-595.
13. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel,doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocytecolony stimulating factor to the TAC regimen. Ann Oncol. 2006;17:1205-1212. (Pubitemid 44288210)
14. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med. 2005;352:2302-2313. (Pubitemid 40740554)
15. Mittmann N, Verma S, Koo M, Alloul K, Trudeau M. Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer. Curr Oncol. 2010;17:7-16.
16. Mousavi SM, Gouya MM, Ramazani R, et al. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20:556-563.
17. Naghavi M. Epidemiology of mortality in 23 provinces of Iran 2003. Tehran, Iran: Ministry of Health, Deputy to Health Directory, Research and Development Office; 2005.
18. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: How reliable is the relationship? Health Qual Life Outcomes. 2009;7:27.
19. Sadjadi A, Nouraie M, Mohagheghi MA, et al. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005;6:359-363.
20. Sintonen H. The 15D instrument of health-related quality of life: Properties and applications. Ann Med. 2001;33:328-336. (Pubitemid 32675373)
21. Soinin EJO, Garcia San Andres B, Joensuu T. Trabectedin in the treatment of metastatic soft tissue sarcoma:Cost-effectiveness, cost-utility and value of information. Ann Oncol. 2011;22:215-223.
22. WHO. The global burden of disease: 2004 update. Geneva:World Health Organization.
23. Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin&cyclophosphamide as adjuvant treatment for early node positive breast cancer: A cost effectiveness & cost utility analysis. J Clin Oncol. 2008;26:925-933. (Pubitemid 351398086)